Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis

Overview of attention for article published in Frontiers in Public Health, March 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,131 followers.

New Research: Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis: Objective The goal of this study is to compare the cost-effectiveness of… https://t.co/oxOJIJ390f #PublicHea

18 Mar 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.